S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
66,000% upside on tiny biotech? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
66,000% upside on tiny biotech? (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
66,000% upside on tiny biotech? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
NASDAQ:VAXX

Vaxxinity (VAXX) Stock Forecast, Price & News

$1.99
+0.01 (+0.51%)
(As of 06/8/2023 ET)
Compare
Today's Range
$1.92
$2.04
50-Day Range
$1.73
$2.42
52-Week Range
$1.24
$4.47
Volume
118,956 shs
Average Volume
131,781 shs
Market Capitalization
$251.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VAXX stock logo

About Vaxxinity (NASDAQ:VAXX) Stock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Stock News Headlines

Vaxxinity (NASDAQ:VAXX) Stock Price Down 7%
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Vaxxinity (NASDAQ:VAXX) Issues Quarterly Earnings Results
Nektar Therapeutics (NKTR) was downgraded to a Sell Rating at Jefferies
Why Shares of Vaxxinity Jumped This Week
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)
Vaxxinity, Inc. (VAXX)
See More Headlines

VAXX Price History

VAXX Company Calendar

Last Earnings
3/27/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VAXX
Fax
N/A
Employees
87
Year Founded
N/A

Profitability

Net Income
$-75,220,000.00
Pretax Margin
-603,670.63%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
$0.49 per share

Miscellaneous

Free Float
51,793,000
Market Cap
$251.81 million
Optionable
Not Optionable
Beta
2.71

Key Executives

  • Mr. Louis Garfield Reese IV (Age 41)
    Co-Founder & Exec. Chairman
    Comp: $83.28k
  • Ms. Mei Mei Hu J.D. (Age 40)
    CEO & Director
    Comp: $551.73k
  • Mr. Rene Paula Molina J.D. (Age 45)
    Sr. VP of Legal & Bus. Affairs, Gen. Counsel & Sec.
    Comp: $480.13k
  • Dr. Ulo Palm M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $585k
  • Mr. Jason Pesile CPA (Age 50)
    M.B.A., Sr. VP of Fin. & Accounting
  • Mr. Dwayne Soisson
    VP of Operations
  • Mr. Jon Harrison
    Chief Gov. Officer
  • Mr. Mark Joinnides
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer
  • Dr. Jean-Cosme Dodart Ph.D.
    Sr. VP of Research













VAXX Stock - Frequently Asked Questions

How have VAXX shares performed in 2023?

Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX shares have increased by 42.1% and is now trading at $1.99.
View the best growth stocks for 2023 here
.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VAXX earnings forecast
.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) posted its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16).

What ETF holds Vaxxinity's stock ?

ETFMG Treatments Testing and Advancements ETF holds 43,836 shares of VAXX stock, representing 0.52% of its portfolio.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

What is Vaxxinity's stock symbol?

Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX."

Who are Vaxxinity's major shareholders?

Vaxxinity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.30%), Bank of America Corp DE (0.25%), Susquehanna International Group LLP (0.24%), State Street Corp (0.10%), HRT Financial LP (0.05%) and Squarepoint Ops LLC (0.04%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc.
View institutional ownership trends
.

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxxinity's stock price today?

One share of VAXX stock can currently be purchased for approximately $1.99.

How much money does Vaxxinity make?

Vaxxinity (NASDAQ:VAXX) has a market capitalization of $251.81 million and generates $70,000.00 in revenue each year. The company earns $-75,220,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How can I contact Vaxxinity?

The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com.

This page (NASDAQ:VAXX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -